Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sexual Behavior | 4 | 2014 | 320 | 0.210 |
Why?
|
| HIV Infections | 7 | 2016 | 5097 | 0.200 |
Why?
|
| HIV-1 | 3 | 2016 | 1260 | 0.190 |
Why?
|
| Aflatoxin B1 | 1 | 2001 | 2 | 0.180 |
Why?
|
| Carcinogens | 1 | 2001 | 6 | 0.180 |
Why?
|
| Lung | 1 | 2001 | 70 | 0.180 |
Why?
|
| Empirical Research | 1 | 2016 | 1 | 0.140 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 3 | 2014 | 24 | 0.130 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2014 | 103 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2016 | 225 | 0.120 |
Why?
|
| Deoxycytidine | 1 | 2015 | 12 | 0.120 |
Why?
|
| Organophosphonates | 1 | 2015 | 45 | 0.120 |
Why?
|
| Adenine | 1 | 2015 | 91 | 0.120 |
Why?
|
| Research Subjects | 1 | 2014 | 4 | 0.120 |
Why?
|
| Spouse Abuse | 1 | 2014 | 12 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 34 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 57 | 0.110 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 196 | 0.100 |
Why?
|
| Young Adult | 6 | 2015 | 2498 | 0.090 |
Why?
|
| Self Disclosure | 1 | 2011 | 8 | 0.090 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2011 | 16 | 0.090 |
Why?
|
| Naphthalenesulfonates | 1 | 2010 | 2 | 0.090 |
Why?
|
| Adolescent | 6 | 2015 | 2985 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 551 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2011 | 203 | 0.090 |
Why?
|
| Polymers | 1 | 2010 | 133 | 0.090 |
Why?
|
| Adult | 7 | 2016 | 5913 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2010 | 111 | 0.080 |
Why?
|
| Administration, Intravaginal | 3 | 2015 | 50 | 0.080 |
Why?
|
| Women's Health | 1 | 2008 | 41 | 0.080 |
Why?
|
| Humans | 9 | 2016 | 14537 | 0.070 |
Why?
|
| Female | 7 | 2016 | 9103 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2014 | 272 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 1324 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2003 | 4 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2003 | 25 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 99 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2014 | 121 | 0.050 |
Why?
|
| Africa South of the Sahara | 2 | 2015 | 353 | 0.050 |
Why?
|
| Formazans | 1 | 2001 | 1 | 0.050 |
Why?
|
| Epithelioid Cells | 1 | 2001 | 1 | 0.050 |
Why?
|
| Tetrazolium Salts | 1 | 2001 | 3 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 20 | 0.050 |
Why?
|
| South Africa | 5 | 2014 | 7596 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 685 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 563 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 188 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 244 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 376 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2016 | 215 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2015 | 78 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 127 | 0.030 |
Why?
|
| Middle Aged | 2 | 2015 | 3601 | 0.030 |
Why?
|
| Narration | 1 | 2014 | 10 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 279 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 2014 | 15 | 0.030 |
Why?
|
| Patient Selection | 1 | 2014 | 40 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 106 | 0.030 |
Why?
|
| Tenofovir | 1 | 2015 | 171 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 163 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 2014 | 60 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2015 | 151 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2014 | 101 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2015 | 278 | 0.030 |
Why?
|
| Age Factors | 1 | 2014 | 370 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 265 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 321 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 1475 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 889 | 0.020 |
Why?
|
| Computers | 1 | 2011 | 5 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2011 | 4 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 120 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 88 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 327 | 0.020 |
Why?
|
| Carrageenan | 1 | 2008 | 3 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 411 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 76 | 0.020 |
Why?
|
| Pregnancy | 1 | 2014 | 1862 | 0.020 |
Why?
|
| Male | 1 | 2016 | 6754 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2003 | 11 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 122 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 143 | 0.010 |
Why?
|